In addition, the TCGA cohort showed that gliomas with high TNFRSF19 levels had higher amounts of 28 immune checkpoint proteins, such as PD-L1, and lower levels of six immune checkpoint genes compared to those with low TNFRSF14 levels (P < 0.05, Fig. 8A). The gene discussed is TNFRSF14; the disease is glioma.